Loading clinical trials...
Loading clinical trials...
A PHASE 3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLINDED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER
Conditions
Interventions
Clostridium difficile vaccine
Placebo
Locations
426
United States
North Alabama Research Center, LLC
Athens, Alabama, United States
Medical Affiliated Research Center, Inc.
Huntsville, Alabama, United States
Coastal Clinical Research, LLC, An AMR Company
Mobile, Alabama, United States
The Pain Center of Arizona
Peoria, Arizona, United States
Phoenix VA Health Care System
Phoenix, Arizona, United States
Phoenix Clinical LLC
Phoenix, Arizona, United States
Start Date
March 29, 2017
Primary Completion Date
December 21, 2021
Completion Date
December 21, 2021
Last Updated
February 13, 2023
NCT06237452
NCT03325855
NCT04014413
NCT04940468
NCT04003818
NCT05826418
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions